ACUTE KIDNEY INJURY AS A PREDICTOR OF IN-HOSPITAL MORTALITY IN PATIENTS WITH A DIAGNOSIS OF SEVERE COVID-19

Abstract

SUMMARY OBJECTIVE: Determine if Acute Kidney Injury (AKI) is a predictor of In-hospital Mortality in severe Covid-19 patients. METHODS: A retrospective cohort study was carried out with severe Covid-19 patients from the Hospital de la Amistad Peru - Corea Santa Rosa II - Piura, using a multivariate analysis with the bivariate logistic regression technique and the method = Advance by steps (ratio of likelihood), to calculate a predictive model for Mortality in Covid-19 patients exposed to ARI. RESULTS: Mortality was higher in the cohort exposed to ARI (95% vs 71.9%) and a 5-fold RR of death in the patient exposed to ARI compared to the Covid-19 patient not exposed to ARI. CONCLUSION: Exposure to ARI increases the risk of mortality by 5 times, increasing the risk of mortality based on the increase in the SOFA score upon admission to the ICU and increase in mg/dl of C-Reactive Protein. Keywords : Acute Kidney Injury, Mortality, severe Covid-19, Retrospective Cohort.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study did not receive any funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The IRB of the Hospital de la Amistad Peru Corea Santa Rosa II gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors. All data produced in the present work are contained in the manuscript.

留言 (0)

沒有登入
gif